Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.42 is in line with its 5-year average of -1.40, near the high end of its 5-year range (-2.56–-1.04).
As of the fiscal period ended Wednesday, December 31, 2025. 7.58% below its 12-month average of -1.32.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.35.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.42
EARNINGS PER SHARE (EPS) AVG TTM
-1.32
EARNINGS PER SHARE (EPS) AVG 3Y
-1.19
EARNINGS PER SHARE (EPS) AVG 5Y
-1.40
EARNINGS PER SHARE (EPS) AVG 10Y
-1.60
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.58%
CURRENT VS 3Y AVG
-19.08%
CURRENT VS 5Y AVG
-1.67%
CURRENT VS 10Y AVG
+11.10%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ocular Therapeutix, Inc.
Market Cap
$1.61B
Earnings Per Share (EPS)
-1.42
TTM Avg
-1.32
3Y Avg
-1.19
5Y Avg
-1.40
Market Cap
$1.61B
Earnings Per Share (EPS)
0.84
TTM Avg
0.16
3Y Avg
0.00
5Y Avg
0.42
Market Cap
$1.60B
Earnings Per Share (EPS)
-4.04
TTM Avg
-4.19
3Y Avg
-4.39
5Y Avg
-2.20
Market Cap
$1.61B
Earnings Per Share (EPS)
-0.54
TTM Avg
-1.52
3Y Avg
-1.00
5Y Avg
-1.00
Market Cap
$1.62B
Earnings Per Share (EPS)
-0.72
TTM Avg
-1.04
3Y Avg
-1.27
5Y Avg
-1.30
Market Cap
$1.59B
Earnings Per Share (EPS)
-2.67
TTM Avg
-2.43
3Y Avg
-2.07
5Y Avg
-2.07
Market Cap
$1.63B
Earnings Per Share (EPS)
4.63
TTM Avg
1.23
3Y Avg
0.09
5Y Avg
-0.82
Market Cap
$1.56B
Earnings Per Share (EPS)
-3.36
TTM Avg
-0.89
3Y Avg
-1.69
5Y Avg
-1.77
Market Cap
$1.54B
Earnings Per Share (EPS)
4.10
TTM Avg
2.19
3Y Avg
2.59
5Y Avg
2.64
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $1.61B | -1.42 | -1.32 | -1.19 | -1.40 |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 0.84 | 0.16 | 0.00 | 0.42 |
| uniQure N.V. (QURE)vs › | $1.60B | -4.04 | -4.19 | -4.39 | -2.20 |
| Septerna Inc (SEPN)vs › | $1.61B | -0.54 | -1.52 | -1.00 | -1.00 |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.62B | -0.72 | -1.04 | -1.27 | -1.30 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -2.67 | -2.43 | -2.07 | -2.07 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.63B | 4.63 | 1.23 | 0.09 | -0.82 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.56B | -3.36 | -0.89 | -1.69 | -1.77 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 4.10 | 2.19 | 2.59 | 2.64 |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.53B | -2.52 | -3.51 | -3.12 | -2.29 |
Trailing EPS (TTM)
$-1.42
Forward EPS (Est.)
$-1.50
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.42 |
| 2024-12-31 | -1.22 |
| 2023-12-31 | -1.09 |
| 2022-12-31 | -1.04 |
| 2021-12-31 | -1.05 |
| 2020-12-31 | -2.56 |
| 2019-12-31 | -1.91 |
| 2018-12-31 | -1.57 |
| 2017-12-31 | -2.20 |
| 2016-12-31 | -1.80 |
| 2015-12-31 | -1.71 |
| 2014-12-31 | -2.69 |
| 2013-12-31 | -4.52 |
| 2012-12-31 | -4.78 |
